JP2016533775A5 - - Google Patents

Download PDF

Info

Publication number: JP2016533775A5
Authority: JP; Japan
Prior art keywords: paste; salt; weight; paste composition; composition according
Prior art date: 2014-10-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2016518431A

Other languages

English (en)

Japanese (ja)

Other versions

JP2016533775A (ja

JP6491647B2 (ja

Filing date

2014-10-23

Publication date

2018-09-20

2013-10-24 Priority claimed from US14/061,993 external-priority patent/US9192692B2/en

2014-06-30 Priority claimed from US14/319,901 external-priority patent/US9192574B2/en

2014-10-23 Application filed filed Critical

2016-11-04 Publication of JP2016533775A publication Critical patent/JP2016533775A/ja

2018-09-20 Publication of JP2016533775A5 publication Critical patent/JP2016533775A5/ja

2019-03-27 Application granted granted Critical

2019-03-27 Publication of JP6491647B2 publication Critical patent/JP6491647B2/ja

Status Active legal-status Critical Current

2034-10-23 Anticipated expiration legal-status Critical

Links

229920001661 Chitosan Polymers 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 24
229910019142 PO4 Inorganic materials 0.000 claims description 13
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 13
239000010452 phosphate Substances 0.000 claims description 13
239000000243 solution Substances 0.000 claims description 12
206010052428 Wound Diseases 0.000 claims description 9
208000027418 Wounds and injury Diseases 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
239000000314 lubricant Substances 0.000 claims description 6
239000000080 wetting agent Substances 0.000 claims description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
239000002953 phosphate buffered saline Substances 0.000 claims description 3
XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 claims description 2
230000003013 cytotoxicity Effects 0.000 claims description 2
231100000135 cytotoxicity Toxicity 0.000 claims description 2
231100000065 noncytotoxic Toxicity 0.000 claims description 2
230000002020 noncytotoxic effect Effects 0.000 claims description 2
150000003841 chloride salts Chemical class 0.000 claims 1
150000001860 citric acid derivatives Chemical class 0.000 claims 1
150000002306 glutamic acid derivatives Chemical class 0.000 claims 1
150000003893 lactate salts Chemical class 0.000 claims 1
150000002823 nitrates Chemical class 0.000 claims 1
150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
238000000034 method Methods 0.000 description 19
239000003638 chemical reducing agent Substances 0.000 description 8
229920002807 Thiomer Polymers 0.000 description 5
125000003396 thiol group Chemical class [H]S* 0.000 description 5
238000012377 drug delivery Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000012382 advanced drug delivery Methods 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
238000009509 drug development Methods 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
-1 glutamate salts Chemical class 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000003232 mucoadhesive effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000005060 rubber Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920000926 Galactomannan Polymers 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000031737 Tissue Adhesions Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940023476 agar Drugs 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000010894 electron beam technology Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

JP2016518431A 2013-10-24 2014-10-23 キトサンペースト創傷手当て材 Active JP6491647B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US14/061,993		2013-10-24
US14/061,993 US9192692B2 (en)	2013-10-24	2013-10-24	Chitosan stenting paste
US14/319,901		2014-06-30
US14/319,901 US9192574B2 (en)	2013-10-24	2014-06-30	Chitosan paste wound dressing
PCT/US2014/062041 WO2015061612A1 (en)	2013-10-24	2014-10-23	Chitosan paste wound dressing

Publications (3)

Publication Number	Publication Date
JP2016533775A JP2016533775A (ja)	2016-11-04
JP2016533775A5 true JP2016533775A5 (2)	2018-09-20
JP6491647B2 JP6491647B2 (ja)	2019-03-27

Family

ID=51862592

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2016518431A Active JP6491647B2 (ja)	2013-10-24	2014-10-23	キトサンペースト創傷手当て材
JP2016522114A Active JP6397491B2 (ja)	2013-10-24	2014-10-23	キトサンステント材ペースト

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2016522114A Active JP6397491B2 (ja)	2013-10-24	2014-10-23	キトサンステント材ペースト

Country Status (7)

Country	Link
US (1)	US9192574B2 (2)
EP (2)	EP3060266B1 (2)
JP (2)	JP6491647B2 (2)
AU (2)	AU2014340012B2 (2)
CA (2)	CA2927357A1 (2)
ES (2)	ES2755137T3 (2)
WO (2)	WO2015061612A1 (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8932560B2 (en)	2007-09-04	2015-01-13	University of Maryland, College Parke	Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells
CA2780898A1 (en)	2009-11-13	2011-05-19	University Of Maryland, College Park	Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
CA2914610C (en)	2013-03-13	2022-08-02	University Of Maryland	Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells
EP3569262A1 (en)	2013-03-14	2019-11-20	Tricol Biomedical, Inc.	Biocompatible and bioabsorbable derivatized chitosan compositions
US20180280453A1 (en)	2015-08-27	2018-10-04	Alimentary Health Limited	Use of bifidobacterium longum and an exopolysaccharide produced thereby
US10576099B2 (en)	2016-10-21	2020-03-03	Covidien Lp	Injectable scaffold for treatment of intracranial aneurysms and related technology
US10925997B2 (en) *	2016-10-26	2021-02-23	Biointelligence Systems S.L.	Bone bioactive composition and uses thereof
JP2022519587A (ja) *	2019-02-08	2022-03-24	チトゲルリミテッド	外科用ハイドロゲル
US11305387B2 (en)	2019-11-04	2022-04-19	Covidien Lp	Systems and methods for treating aneurysms
EP4308013A1 (en)	2021-03-16	2024-01-24	Covidien LP	Injectable biopolymer compositions and associated systems and methods
EP4084580A1 (en) *	2021-04-30	2022-11-02	Koninklijke Philips N.V.	A light output system and design method
KR102852787B1 (ko) *	2021-12-28	2025-08-28	단국대학교 천안캠퍼스 산학협력단	신규한 화합물을 포함하는 생리 식염수
EP4572811A1 (en) *	2022-11-10	2025-06-25	Hemostasis LLC	Dressing formulations
CN116059430B (zh) *	2022-12-16	2025-09-23	无锡学院	一种可降解伤口敷料及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4394373A (en)	1981-04-06	1983-07-19	Malette William Graham	Method of achieving hemostasis
US4532134A (en)	1981-04-06	1985-07-30	Malette William Graham	Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound
US4452785A (en)	1982-11-08	1984-06-05	Malette William Graham	Method for the therapeutic occlusion
CA1202904A (en)	1983-11-21	1986-04-08	Brian G. Sparkes	Chitosan based wound dressing materials
US4659700A (en)	1984-03-02	1987-04-21	Johnson & Johnson Products, Inc.	Chitosan-glycerol-water gel
JPH0735281B2 (ja)	1988-02-16	1995-04-19	学校法人松本歯科大学	硬化性組成物
US4956350A (en)	1988-08-18	1990-09-11	Minnesota Mining And Manufacturing Company	Wound filling compositions
US5124151A (en)	1990-08-07	1992-06-23	Mediventures Inc.	Drug delivery by injection with thermo-irreversible gels
US5318780A (en)	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
US5871985A (en)	1992-09-28	1999-02-16	Brown University Research Foundation	Particulate non cross-linked chitosan core matrices for encapsulated cells
GB2276819B (en)	1993-03-23	1996-12-11	Johnson & Johnson Medical	Aqueous wound treatment composition comprising a polysaccharide and hexylene glycol
US5531716A (en)	1993-09-29	1996-07-02	Hercules Incorporated	Medical devices subject to triggered disintegration
US5622834A (en)	1993-12-01	1997-04-22	Marine Polymer Technologies, Inc.	Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
SE9402531L (sv)	1994-07-19	1996-01-20	Medicarb Ab	Sårläkningsmedel
GB9421969D0 (en)	1994-10-28	1994-12-21	Innovative Tech Ltd	Wound treatment composition
USRE38431E1 (en)	1995-12-01	2004-02-17	The American National Red Cross	Methods of production and use of liquid formulations of plasma proteins
WO1998051709A1 (en)	1997-05-13	1998-11-19	Young Keun Hong	Aqueous cellulose solution and rayon fiber produced from the same
CA2212300A1 (en)	1997-08-04	1999-02-04	Abdellatif Chenite	In vitro or in vivo gelfying chitosan and therapeutic uses thereof
US6458375B1 (en)	1998-02-27	2002-10-01	Musculoskeletal Transplant Foundation	Malleable paste with allograft bone reinforcement for filling bone defects
ATE243049T1 (de)	1999-12-09	2003-07-15	Biosyntech Canada Inc	Mineral-polymer hybrid-zusammensetzung
IL153490A0 (en)	2000-06-29	2003-07-06	Biosyntech Canada Inc	Composition and method for the repair and regeneration of cartilage and other tissues
EP1190702A1 (en)	2000-09-22	2002-03-27	Ciba SC Holding AG	Chitosan emulsion formulation
CA2429165A1 (en)	2000-11-15	2002-05-23	Bio Syntech Canada Inc.	Filler composition for soft tissue augmentation and reconstructive surgery
US20020058704A1 (en)	2000-11-15	2002-05-16	Kimberly-Clark Worldwide, Inc.	Multicomponent compositions containing chitosan and methods of preparing same
ATA13842001A (de)	2001-08-31	2002-10-15	Mucobiomer Biotechnologische F	Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
EP1448607B1 (en)	2001-11-15	2011-01-05	Biosyntech Canada Inc.	Composition and method to homogeneously modify or cross-link chitosan under neutral conditions
JP3947391B2 (ja)	2001-11-28	2007-07-18	独立行政法人日本原子力研究開発機構	橋かけ構造を有するキチン誘導体及び／又はキトサン誘導体の製造方法
FR2836044A1 (fr)	2002-02-15	2003-08-22	Octaris	Composition pour la reparation et la cicatrisation cutanee comprenant exclusivement un vrai hydrogel physique de chitosane
ATE481110T1 (de)	2002-07-16	2010-10-15	Biosyntech Canada Inc	Zusammensetzung für die herstellung zellkompatibler, injizierbarer, selbstgelierender chitosan lösungen zum einkapseln und verabreichen von lebenden zellen oderbiologisch aktiven faktoren
GB2393120A (en)	2002-09-18	2004-03-24	Johnson & Johnson Medical Ltd	Compositions for wound treatment
JP5102435B2 (ja)	2002-10-08	2012-12-19	株式会社リコム	キトサン含有多糖、その製造方法及び用途
JP2006347883A (ja) *	2003-09-08	2006-12-28	Neetec:Kk	糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物
US7968122B2 (en)	2003-12-10	2011-06-28	Adventrx Pharmaceuticals, Inc.	Anti-viral pharmaceutical compositions
US8124120B2 (en)	2003-12-22	2012-02-28	Anika Therapeutics, Inc.	Crosslinked hyaluronic acid compositions for tissue augmentation
GB0329918D0 (en)	2003-12-24	2004-01-28	West Pharm Serv Drug Res Ltd	Intranasal compositions
GB0403938D0 (en)	2004-02-21	2004-03-24	West Pharm Serv Drug Res Ltd	Chitosan containing solution
JP2005281654A (ja) *	2004-03-31	2005-10-13	Rikogaku Shinkokai	温度応答性組成物およびそのヒドロゲル
ITRM20040539A1 (it)	2004-11-02	2005-02-02	Mavi Sud S R L	Preparati a base di chitina o suoi derivati per uso cosmetico o medico.
CN101098718A (zh)	2004-12-20	2008-01-02	卡博格拉夫特有限公司	壳聚糖组合物
US20060287278A1 (en)	2005-06-21	2006-12-21	Zhenze Hu	Method for improving water solubility of chitosan
EP1945712A4 (en)	2005-11-04	2013-05-01	Piramal Healthcare Canada Ltd	BINDING OF AQUEOUS POLYELECTROLYTE SOLUTIONS BY THERMALLY INDUCED CHANGES IN THE IONIZATION CONDITION
US8536230B2 (en)	2006-01-25	2013-09-17	University Of Virginia Patent Foundation	Methods for regulating gelation of polysaccharide solutions and uses thereof
US8431160B2 (en)	2006-02-24	2013-04-30	Novartis Ag	Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
US7976873B2 (en)	2006-05-10	2011-07-12	Medtronic Xomed, Inc.	Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US20070264296A1 (en)	2006-05-10	2007-11-15	Myntti Matthew F	Biofilm extracellular polysachharide solvating system
US7959943B2 (en)	2006-05-10	2011-06-14	Medtronics Xomed, Inc.	Solvating system and sealant for medical use in the middle or inner ear
WO2008127287A2 (en)	2006-10-11	2008-10-23	Biolife, L.L.C.	Materials and methods for wound treatment
US8153612B2 (en)	2006-12-11	2012-04-10	Chi2Gel Ltd.	Injectable chitosan mixtures forming hydrogels
US20100172953A1 (en)	2007-06-13	2010-07-08	Fmc Corporation	Biopolymer Based Implantable Degradable Devices
JP5725862B2 (ja)	2007-10-30	2015-05-27	ヴィスコゲルアーベーＶｉｓｃｏｇｅｌＡｂ	キトサン組成物
WO2009114535A2 (en)	2008-03-10	2009-09-17	Marfly 2, Lp	Bone paste composition
WO2009132229A2 (en)	2008-04-24	2009-10-29	Medtronic, Inc.	Cold ionizing radiation sterilization
EP2313104B2 (en)	2008-04-24	2020-08-26	Medtronic, Inc	Thiolated chitosan gel
CN102883715B (zh)	2008-04-24	2014-11-12	麦德托尼克公司	包含壳聚糖的保护性组合物
ES2759373T3 (es)	2008-06-12	2020-05-08	Medtronic Xomed Inc	Producto para el tratamiento de heridas crónicas con un sistema extracelular de solvatación de sustancias poliméricas
WO2010033943A1 (en)	2008-09-19	2010-03-25	The Trustees Of The University Of Pennsylvania	Biodegradable stent
CA3004707C (en)	2009-09-02	2022-05-31	Synedgen Inc.	Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
WO2011060545A1 (en)	2009-11-19	2011-05-26	Corporation De L'ecole Polytechnique De Montreal	Specific blood:chitosan mixing ratios producing a viscous paste-like implant with good handling properties for tissue repair
ES2691723T3 (es)	2009-11-19	2018-11-28	Ortho Regenerative Technologies Inc.	Formulaciones de quitosán fisiológicas solubles combinadas con plasma rico en plaquetas (PRP) para reparación de tejidos
CN102469782A (zh)	2010-06-18	2012-05-23	哈洛资源公司	包含壳聚糖的固态共混物的制剂及方法
US8506972B2 (en)	2010-08-27	2013-08-13	Oligo Medic Inc	Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions

2014
- 2014-06-30 US US14/319,901 patent/US9192574B2/en active Active
- 2014-10-23 CA CA2927357A patent/CA2927357A1/en not_active Abandoned
- 2014-10-23 EP EP14793731.2A patent/EP3060266B1/en active Active
- 2014-10-23 WO PCT/US2014/062041 patent/WO2015061612A1/en not_active Ceased
- 2014-10-23 JP JP2016518431A patent/JP6491647B2/ja active Active
- 2014-10-23 WO PCT/US2014/062029 patent/WO2015061606A1/en not_active Ceased
- 2014-10-23 AU AU2014340012A patent/AU2014340012B2/en active Active
- 2014-10-23 ES ES14793731T patent/ES2755137T3/es active Active
- 2014-10-23 ES ES14793730T patent/ES2765348T3/es active Active
- 2014-10-23 AU AU2014340006A patent/AU2014340006B2/en active Active
- 2014-10-23 CA CA2926401A patent/CA2926401C/en not_active Expired - Fee Related
- 2014-10-23 EP EP14793730.4A patent/EP3060265B1/en active Active
- 2014-10-23 JP JP2016522114A patent/JP6397491B2/ja active Active

Publication	Publication Date	Title
JP2016533775A5 (2)	2018-09-20
Frigaard et al.	2022	The potential of chitosan in nanomedicine: an overview of the cytotoxicity of chitosan based nanoparticles
Bhat et al.	2022	Polysaccharide-based nanomedicines targeting lung cancer
Osmałek et al.	2021	Recent advances in polymer-based vaginal drug delivery systems
Pistone et al.	2017	Formulation of polysaccharide-based nanoparticles for local administration into the oral cavity
JP6491647B2 (ja)	2019-03-27	キトサンペースト創傷手当て材
Vecchies et al.	2018	Complex coacervates between a lactose-modified chitosan and hyaluronic acid as radical-scavenging drug carriers
Muhsin et al.	2016	Effects of chemical conjugation of L-leucine to chitosan on dispersibility and controlled release of drug from a nanoparticulate dry powder inhaler formulation
Kumar et al.	2016	Ciprofloxacin loaded genipin cross-linked chitosan/heparin nanoparticles for drug delivery application
AU2014340006A1 (en)	2016-05-12	Chitosan stenting paste
US20260060999A1 (en)	2026-03-05	Reinforcement of mucus barrier properties
US20150119357A1 (en)	2015-04-30	Chitosan stenting paste
AU2014340012A1 (en)	2016-05-12	Chitosan paste wound dressing
Qian et al.	2025	In situ gels for nasal delivery: Formulation, characterization and applications
JP2019513837A (ja)	2019-05-30	フィトグリコーゲンナノ粒子を含む抗感染症組成物
Bosio et al.	2014	Tailoring doxorubicin sustainable release from biopolymeric smart matrix using congo red as molecular helper
Depani et al.	2013	Preparation and evaluation of chitosan based thermoreversible gels for intraperitoneal delivery of 5-fluorouracil (5-FU)
JP6499220B2 (ja)	2019-04-10	関節内補充療法のためのポリマー溶液
CN106963958B (zh)	2019-10-08	多糖水溶液的灭菌方法及无菌的多糖水溶液
Jana et al.	2022	Nanoengineering of biomaterials: Drug delivery & biomedical applications
CN108096272B (zh)	2021-07-23	一种儿童皮肤用抗真菌感染产品及其制备方法
Khushbu	2022	Carboxymethyl tamarind kernel gum based controlled drug delivery excipients: a review
Cadinoiu et al.	2019	Biocompatible injectable polysaccharide materials for drug delivery
TWI543777B (zh)	2016-08-01	溫敏型可注射式青光眼藥物載體凝膠及其製備方法
KR20220075345A (ko)	2022-06-08	지속 방출 하이드로겔 조성물